Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR.
Aged
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Bortezomib
/ administration & dosage
Dexamethasone
/ administration & dosage
Drug Resistance, Neoplasm
Female
Follow-Up Studies
Humans
Male
Multiple Myeloma
/ complications
Neoplasm Recurrence, Local
/ drug therapy
Oligopeptides
/ administration & dosage
Prognosis
Prospective Studies
Renal Insufficiency
/ drug therapy
Survival Rate
Journal
Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509
Informations de publication
Date de publication:
10 01 2019
10 01 2019
Historique:
received:
27
06
2018
accepted:
27
10
2018
pubmed:
28
11
2018
medline:
21
8
2019
entrez:
28
11
2018
Statut:
ppublish
Résumé
In ENDEAVOR, carfilzomib (56 mg/m
Identifiants
pubmed: 30478094
pii: S0006-4971(20)42877-0
doi: 10.1182/blood-2018-06-860015
pmc: PMC6346374
doi:
Substances chimiques
Oligopeptides
0
Bortezomib
69G8BD63PP
carfilzomib
72X6E3J5AR
Dexamethasone
7S5I7G3JQL
Banques de données
ClinicalTrials.gov
['NCT01568866']
Types de publication
Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
147-155Informations de copyright
© 2019 by The American Society of Hematology.
Références
Mayo Clin Proc. 2003 Jan;78(1):21-33
pubmed: 12528874
Leukemia. 2017 Jan;31(1):107-114
pubmed: 27416912
Ann Hematol. 2016 May;95(6):931-6
pubmed: 27068406
N Engl J Med. 2003 Jun 26;348(26):2609-17
pubmed: 12826635
Cancer Med. 2017 Jul;6(7):1523-1530
pubmed: 28612485
Mayo Clin Proc. 2004 Jul;79(7):867-74
pubmed: 15244382
Blood. 2016 Jul 7;128(1):37-44
pubmed: 27216216
Lancet Oncol. 2017 Oct;18(10):1327-1337
pubmed: 28843768
Blood. 2007 Mar 15;109(6):2604-6
pubmed: 17138816
Lancet Oncol. 2016 Jan;17(1):27-38
pubmed: 26671818
Leukemia. 2015 May;29(5):1195-201
pubmed: 25640885
Adv Chronic Kidney Dis. 2012 Sep;19(5):333-41
pubmed: 22920644
J Clin Pharmacol. 2007 Dec;47(12):1466-75
pubmed: 17954615
Lancet Oncol. 2013 Oct;14(11):1055-1066
pubmed: 24007748
J Clin Oncol. 2016 May 1;34(13):1544-57
pubmed: 26976420
Ther Adv Hematol. 2013 Dec;4(6):354-65
pubmed: 24319571
Med Clin North Am. 2005 May;89(3):649-87
pubmed: 15755472
Leukemia. 2013 Aug;27(8):1707-14
pubmed: 23364621
N Engl J Med. 2005 Jun 16;352(24):2487-98
pubmed: 15958804
J Clin Oncol. 2009 Dec 20;27(36):6086-93
pubmed: 19858394
Clin Pharmacol. 2014 May 08;6:87-96
pubmed: 24855395
Leuk Lymphoma. 2017 Sep;58(9):1-9
pubmed: 28278719
Clin Lymphoma Myeloma Leuk. 2016 May;16(5):241-5
pubmed: 26907720
Blood Cancer J. 2015 Mar 20;5:e296
pubmed: 25794132
N Engl J Med. 2016 Apr 28;374(17):1621-34
pubmed: 27119237
Br J Haematol. 2007 Sep;138(5):640-3
pubmed: 17686058
Leuk Res. 2010 Oct;34(10):1395-7
pubmed: 20510452
Lancet Oncol. 2010 Jan;11(1):29-37
pubmed: 19853510
Cancer Chemother Pharmacol. 2017 Jun;79(6):1067-1076
pubmed: 28424963
Haematologica. 2013 Nov;98(11):1753-61
pubmed: 23935022
Leuk Lymphoma. 2007 Feb;48(2):337-41
pubmed: 17325894
Clin Lymphoma Myeloma Leuk. 2016 Mar;16(3):129-38
pubmed: 26795075
Arch Pathol Lab Med. 2004 Aug;128(8):875-9
pubmed: 15270616
Medicine (Baltimore). 2016 Nov;95(46):e5202
pubmed: 27861343
Clin Lymphoma Myeloma. 2009 Aug;9(4):302-6
pubmed: 19717380
Am J Hematol. 2011 Aug;86(8):640-5
pubmed: 21630308
N Engl J Med. 2015 Jan 8;372(2):142-52
pubmed: 25482145
J Clin Oncol. 2018 Jul 10;36(20):2035-2043
pubmed: 29394124